FDA Clears First OTC CGM for Children: Dexcom Expands Stelo
Decision brief
Answer first · skim in under a minute
The FDA has cleared Dexcom Inc.’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children. The decision extends Stelo’s prior OTC clearance in adults and gives analysts a new regulatory catalyst to track in diabetes monitoring.
The list of FDA approved glucose meters and related CGM systems expanded on June 12, 2026, when FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people age 2 and older who do not use insulin.
Contents10 sections
Key Takeaways
- FDA cleared Stelo as the first OTC CGM for children age 2+, expanding the March 2024 adult OTC clearance.
- Indication covers non-insulin users, including some children with diabetes on oral medicines and lifestyle glucose tracking.
- Pediatric use requires adult caregiver supervision; Stelo is not for problematic hypoglycemia or dialysis.
- The wearable updates about every 15 minutes and is designed for up to 15 days of wear.
What did FDA clear for pediatric OTC CGM use?
FDA’s June 12, 2026 press announcement states that Stelo is the first OTC continuous glucose monitor cleared for children. The agency previously cleared Stelo OTC for adults 18 and older in March 2024. Official details are on the FDA Stelo pediatric clearance page.
Where does Stelo sit on the list of FDA approved glucose meters?
Traditional fingerstick meters remain widely available, while prescription CGMs serve many insulin users. Stelo fills a different slot: an over-the-counter integrated CGM for people who do not use insulin. Competing OTC adult CGMs may remain adult-only; FDA’s announcement positions Stelo as the first OTC CGM option in the pediatric age band.
For diabetes epidemiology context that frames why pediatric glucose tools matter, see the CDC diabetes hub.
Who should not use Stelo?
FDA warns that Stelo is not designed to alert users to problematic hypoglycemia and is not for people on dialysis. People with disordered eating history should talk with a clinician before use. Children need adult caregiver supervision.
How does the device work day to day?
Stelo is worn on the body and pairs with a smart-device application. Glucose readings update about every 15 minutes to support measurement, recording, and analysis. Sensors are replaced after about 15 days. Related industry commentary on future CGM use cases appears in NovaPharma’s Dexcom coverage.
Why this clearance matters for device and payer teams
Expanding OTC CGM into pediatrics changes retail pharmacy and e-commerce assortments, caregiver education needs, and competitive timing versus other OTC CGM brands still limited to adults. Real-world evidence figured in FDA’s framing of the pediatric decision pathway.
Device performance expectations should be checked against the cleared labeling and any related clinical registrations such as ClinicalTrials.gov NCT07425236 when reviewing pediatric evidence packages.
What remains unproven
Clearance does not prove that OTC pediatric CGM use improves long-term HbA1c or reduces complications in every non-insulin cohort. Comparative effectiveness versus prescription pediatric CGMs for insulin users is outside this indication. Access, caregiver adherence, and false-reassurance risks in hypoglycemia-prone children remain open questions.
Related NovaPharma coverage
- Future Uses for CGM: Insights from Dexcom's CEO
- FDA expands Tzield to certain pediatric patients with recent Stage 3 T1D
- Weight Loss Medications in 2026: GLP-1 Market Shift
Frequently Asked Questions
What changed on the list of FDA approved glucose meters for children?
On June 12, 2026, FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for people two years of age and older who do not use insulin, expanding the prior March 2024 adult OTC clearance.
Who can use Stelo among FDA approved glucose meters?
Stelo is indicated for non-insulin users age 2 and older, including children with diabetes on oral medication and people tracking diet or exercise effects on glucose. In children it should be used under adult caregiver supervision. It is not for people with problematic hypoglycemia or people on dialysis.
How long does the Stelo sensor last?
Stelo is a wearable integrated CGM that pairs with a smart-device app, updates glucose data about every 15 minutes, and is designed for up to 15 days of wear before replacement.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Stelo Glucose Biosensor System.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
